FDA Etcamah Accelerated Approval: ESR1-Mutated Breast Cancer Therapy

• The FDA granted accelerated approval to AstraZeneca's Etcamah (camizestrant) for adult patients with specific advanced breast cancer.
• This therapy targets ESR1 mutations in HR-positive, HER2-negative, locally advanced or metastatic breast cancer, used in combination with a CDK4/6 inhibitor.
• The Guardant360 CDx assay was authorized as a companion diagnostic to identify patients with ESR1 mutations via circulating tumor DNA (ctDNA).
• Efficacy was supported by a clinical trial showing an estimated median progression-free survival of 16 months for Etcamah compared to 9.2 months for the control arm.
• This marks the first FDA approval of a cancer therapy guided by ctDNA resistance mutation detection before imaging shows disease progression, with confirmatory studies required and a boxed warning for irregular heart rhythm.

This landmark decision represents the first instance of the FDA approving a cancer therapy guided by the detection of a resistance mutation in circulating tumor DNA before imaging tests indicate disease progression.

The U.S. Food and Drug Administration (FDA) has expanded therapeutic options for adults battling advanced breast cancer, signaling its ongoing commitment to fostering medical innovation and expediting access to crucial treatments. The agency recently granted accelerated approval to Etcamah (camizestrant), developed by AstraZeneca. This novel oral tablet is indicated for adult patients diagnosed with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer. Its use is specifically authorized when an estrogen receptor-1 (ESR1) mutation is identified during prior treatment with an aromatase inhibitor and a CDK4/6 inhibitor, and it must be administered in combination with an existing CDK4/6 inhibitor, such as abemaciclib, palbociclib, or ribociclib.

ESR1 mutations are acquired resistance mutations that can emerge in tumors during treatment with aromatase inhibitors, which are a common initial endocrine therapy for locally advanced or metastatic breast cancer. While fewer than five percent of patients present with this tumor mutation at the time of HR-positive metastatic breast cancer diagnosis, its prevalence significantly increases to nearly 40 percent after disease progression on an aromatase inhibitor. Acting FDA Commissioner Kyle Diamantas, J.D., underscored the importance of this development, stating that patients with metastatic breast cancer face continuous challenges as their tumors adapt to evade treatment, and that providing targeted therapies designed to overcome resistance offers them more time before disease progression.

The approval of Etcamah hinges on its ability to target these acquired ESR1 mutations, which represent a significant mechanism of resistance to standard endocrine therapies. This therapeutic approach is particularly noteworthy for its reliance on advanced diagnostic methods. To ensure precise patient selection, the FDA also authorized the Guardant360 CDx assay as a companion diagnostic device. This test is crucial for identifying breast cancer patients who possess the ESR1 mutations, thereby guiding treatment decisions for camizestrant.

A key innovation highlighted by this approval is the utilization of circulating tumor DNA (ctDNA). These minute fragments of tumor DNA, released into the bloodstream, enable earlier molecular detection of resistance mutations than traditional imaging methods. The efficacy of Etcamah was evaluated in a clinical trial that compared switching to Etcamah in combination with a CDK4/6 inhibitor against continuing an aromatase inhibitor alongside a CDK4/6 inhibitor. Patients receiving Etcamah demonstrated an estimated median progression-free survival of 16 months, significantly outperforming the 9.2 months observed in the control arm.

The FDA granted this approval through its accelerated approval program, a pathway designed to expedite the availability of drugs for serious conditions that address an unmet medical need, based on surrogate or intermediate endpoints. For Etcamah, the accelerated approval was predicated on the duration patients lived without their disease worsening, measured from the initial detection of the resistance mutation in their blood. However, because it is not yet definitively confirmed whether intervening at this early stage, rather than at the point of confirmed disease progression, translates into a clinically meaningful overall benefit, the FDA has mandated confirmatory studies. These studies are essential to verify and fully characterize the clinical benefits of the treatment.

Angelo de Claro, M.D., director of the FDA’s Oncology Center of Excellence, lauded the commitment of both the FDA and the sponsor to advancing cancer care through this accelerated approval. He emphasized that while this marks a significant milestone as the first FDA approval of a cancer therapy guided by resistance mutation detection in ctDNA prior to imaging evidence of disease progression, additional evidence is still required to confirm the full clinical benefit.

The prescribing information for Etcamah includes a boxed warning concerning the risk of irregular heart rhythm when the drug is co-administered with certain other medications. Furthermore, warnings and precautions are noted for an abnormally slow heart rate and potential harm to an unborn baby. The Oncologic Drugs Advisory Committee convened on April 30, 2026, to discuss this application, with the accelerated approval ultimately granted to AstraZeneca.

This landmark decision represents the first instance of the FDA approving a cancer therapy guided by the detection of a resistance mutation in circulating tumor DNA before imaging tests indicate disease progression. This innovative approach offers a new paradigm for identifying patients who may benefit from targeted therapies earlier in their disease course. By leveraging ctDNA, healthcare providers gain a more sensitive tool for molecular detection, potentially allowing for more timely and effective interventions against evolving tumors.

The approval of Etcamah not only provides a crucial new option for patients facing advanced HR-positive, HER2-negative breast cancer with ESR1 mutations but also establishes a significant precedent for future oncology drug development and regulatory pathways. It underscores the FDA's increasing reliance on advanced biomarker detection and its willingness to utilize the accelerated approval mechanism to bring promising treatments to patients faster, while maintaining rigorous post-market study requirements to confirm long-term clinical efficacy. This development highlights a strategic shift towards more personalized and mutation-driven cancer care.

This approval highlights the FDA's increasing reliance on circulating tumor DNA (ctDNA) for guiding targeted therapies and underscores the ongoing regulatory obligations, including confirmatory studies, for drugs granted accelerated approval. Pharmaceutical companies should note the precedent for ctDNA-guided approvals and ensure compliance with post-market study requirements, while healthcare compliance officers should monitor prescribing information, especially regarding the boxed warning and companion diagnostic use.

Source: Original reporting based on FDA press release.